Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acidCPPTue, October 24th - 5:48 AM 2017
METHODS OF USING (1S, 3S) -3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACIDCPPWed, November 22nd - 8:57 AM 2017
USE (1S,3S)-3-AMINO-4-DIFLUOROMETHYLENYL-1-CYCLOPENTANOIC ACID AS A GABA AMINOTRANSFERSE INHIBITORCPPThu, June 21st - 7:22 AM 2018
Aimmune’s Palforzia gets FDA approval for treatment of peanut allergyPharmaceutical Business ReviewFri, July 27th - 12:14 AM 2018
VERFAHREN ZUR VERWENDUNG VON (1S,3S-)-3-AMINO-4-DIFLUORMETHYLENYL-1-CYCLOPENTAN-SÄURECPPMon, August 12th - 6:15 AM 2019
Harbour BioMed receives FDA IND approval for phase 2 trial and orphan drug designation for HBM9167Pharmaceutical Business ReviewFri, February 28th - 7:12 PM 2020
Boehringer Ingelheim enters discovery stage collaboration with Trutino BiosciencesPharmaceutical Business ReviewFri, February 28th - 7:12 PM 2020
GSK, Innoviva seek EMA approval for Trelegy Ellipta to treat asthma in adultsPharmaceutical Business ReviewFri, February 28th - 7:12 PM 2020
FDA advisory committee votes in favour of Lilly’s CYRAMZA as first-line treatment for metastatic EGFR-mutated NSCLCPharmaceutical Business ReviewFri, February 28th - 7:12 PM 2020
Japan’s Takeda buys PvP Biologics in $330m dealPharmaceutical Business ReviewFri, February 28th - 7:12 PM 2020

Pages